Idoven has developed the world’s first cardiology-as-a-service platform powered by artificial intelligence that augments a clinician’s ability to identify, triage and diagnose patients at scale. Our powerful, proprietary AI software leverages electrocardiogram (ECG) data, of any duration and from any device, to improve the accuracy and consistency of ECG interpretation.

Idoven is a health technology company advancing early detection and precision medicine for cardiovascular diseases. The Idoven AI-powered platform delivers substantial improvements to the speed, consistency, and accuracy of electrocardiogram (ECG) interpretation. Its powerful, proprietary AI algorithms, which work with existing ECG devices, are also being applied to develop disease biomarkers for patient identification, risk stratification, and prognosis, as well as drug cardiac safety monitoring. Idoven partners with leading medical device and pharmaceutical companies on AI-driven innovations to develop a new standard of cardiovascular care. Through exclusive partnerships and research collaborations, Idoven has developed one of the world’s largest ECG databases and a deep learning system applied to cardiology. The Idoven software is designed to be integrated seamlessly into existing clinical and research workflows, to support clinician decision-making and disease management. Idoven has been awarded numerous distinctions for its AI technology in Europe and the US, including the prestigious European Innovation Council (EIC) Accelerator and Horizon 2020 (H2020) awards and the Healthy Longevity Catalyst Award from the US National Academy of Medicine. The company is backed by top-tier investors including Insight Partners, Northzone and Wayra (Telefónica), the Accel Starters program, leading business angels, and EIT Health. Idoven is based in Madrid and was founded in 2018, following almost a decade of ground-breaking research. We are building the future of cardiovasc